Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 204 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omega-3 fatty acid (Eicosapentaenoic acid) Clear all
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Biologic Effects of an Eicosapentaenoic (EPA)-Enriched Oil

NCT00988585
View directory record Official record
Conditions
Heart Disease
Interventions
EPA 600, EPA 1800, Olive Oil, DHA
Dietary Supplement
Lead sponsor
Cardiovascular Research Associates
Network
Eligibility
21 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Not applicable Interventional Results available

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

NCT01285362
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Fish Oil Supplementation, Placebo Supplementation
Drug
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture (VITAL)

NCT01747447
View directory record Official record
Conditions
Bone Density, Body Composition, Bone Health
Interventions
Vitamin D3 placebo, Fish oil placebo, omega-3 fatty acids (fish oil), Vitamin D3
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
771 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

NCT00167310
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease
Interventions
Eicosapentaenoic acid (omega-3 fatty acid), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Not applicable Interventional

Memory Improvement With Docosahexaenoic Acid Study (MIDAS)

NCT00278135
View directory record Official record
Conditions
Age-Related Cognitive Decline, Age-Related Memory Disorders
Interventions
DHA (nutritional supplement) or placebo
Dietary Supplement
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
55 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
14
States / cities
Mesa, Arizona • San Diego, California • Vista, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prenatal DHA and Neurofunctional Development

NCT02709239
View directory record Official record
Conditions
Use and Dose of Prenatal DHA Supplementation
Interventions
DHA 200mg, DHA 800mg
Dietary Supplement
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Age-Related Eye Disease Study 2 (AREDS2)

NCT00345176
View directory record Official record
Conditions
Age-related Macular Degeneration, Cataract
Interventions
Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
Dietary Supplement · Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 85 Years
Enrollment
4,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Not applicable Interventional

Docosahexaenoic Acid in the Treatment of Autism

NCT00577447
View directory record Official record
Conditions
Autism
Interventions
docosahexaenoic acid (DHA), Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 10 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Not applicable Interventional Results available

Effect of EPA and HMB on Strength in ICU Patients

NCT01270516
View directory record Official record
Conditions
Muscle Weakness
Interventions
HMB, hydroxymethylbutyrate, EPA, eicosapentaenoic acid, Saline
Drug
Lead sponsor
Gerald Supinski
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome

NCT00344721
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Omega-3 fatty acid supplement, Placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of DHA on Periodontitis

NCT01976806
View directory record Official record
Conditions
Periodontitis, Gingivitis, Inflammation
Interventions
Aspirin, Docosahexaenoic acid, Placebo (for Docosahexaenoic acid)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Not applicable Interventional Results available

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

NCT00504309
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules, Corn Oil Placebo, 4 capsules/day for 8 weeks
Drug
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Phase 3 Interventional

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

NCT00146211
View directory record Official record
Conditions
Huntington Disease
Interventions
Ethyl-EPA (Miraxion™)
Drug
Lead sponsor
Amarin Neuroscience Ltd
Industry
Eligibility
35 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 9, 2026, 2:45 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Docosahexaenoic Acid (DHA) Supplementation in Amblyopia

NCT03402789
View directory record Official record
Conditions
Amblyopia
Interventions
Docosahexaenoic Acid, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 9, 2026, 2:45 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)

NCT01758081
View directory record Official record
Conditions
Infections, Human Cathelicidin Antimicrobial Peptide (hCAP-18)
Interventions
vitamin D3, omega-3 fatty acids (fish oil), Vitamin D3 placebo, fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,874 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 9, 2026, 2:45 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Bioavailability of EPA and DHA From Two Dietary Supplements

NCT01908374
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
DHA-rich fish oil versus Phospholipid-rich fish oil
Dietary Supplement
Lead sponsor
Arctic Nutrition AS
Industry
Eligibility
18 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy of Fish Oil or Olive Oil Supplementation on the Health Effects of Ozone Exposure in Healthy Young Subjects

NCT03395119
View directory record Official record
Conditions
Healthy, Dietary Supplement
Interventions
Ozone, Fish Oil, Olive Oil
Drug · Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 9, 2026, 2:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Plasma Neurofilament Light and Its Relationship With Omega-3 Status and Soccer Heading in Women Soccer Players

NCT05457023
View directory record Official record
Conditions
Brain Trauma
Interventions
Plasma Neurofilament Light (NF-L), Omega-3 Index, HeadCount Questionnaire
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 9, 2026, 2:45 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension)

NCT01653678
View directory record Official record
Conditions
Hypertension
Interventions
Vitamin D-3 (cholecalciferol), 2000 IU, Omega-3 fatty acids (fish oil), Vitamin D placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 99 Years
Enrollment
25,875 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Phase 3 Interventional

Effect of 8-Week Dietary DHA Supplementation on Cerebral Blood Flow and Metabolic Function

NCT00662142
View directory record Official record
Conditions
Healthy, Attention
Interventions
docosahexaenoic acid
Dietary Supplement
Lead sponsor
University of Cincinnati
Other
Eligibility
8 Years to 10 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 9, 2026, 2:45 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

DHA Supplements to Improve Insulin Sensitivity in Obese Pregnant Women (The Omega-3 Pregnancy Study)

NCT00865683
View directory record Official record
Conditions
Overweight and Obesity, Insulin Resistance, Diabetes, Gestational, Hypertension in Pregnancy, Pre-Eclampsia
Interventions
DHA Supplements, Placebo Supplements
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Oct 9, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

NCT01208961
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Oct 9, 2026, 2:45 PM EDT